Dr. Aroda is Director of Diabetes Clinical Research at Brigham and Women's Hospital and Associate Professor of Medicine at Harvard Medical School. Trained in internal medicine and endocrinology at University of California San Diego, she studies the safety and effectiveness of novel therapies for diabetes, obesity, and cardiometabolic health. A leader in GLP-1 and incretin research, she has helped shape the American Diabetes Association Standards of Care and the ADA-EASD consensus on type 2 diabetes, advancing person-centered treatment and mentorship.

Jorge Plutzky, M.D. is Director, Preventive Cardiology, Brigham and Women’s Hospital (BWH) and an authority on preventive cardiology, including the intersection of obesity, diabetes and atherosclerosis. In addition to studying mechanisms underlying cardio-metabolic disorders in his laboratory, Dr. Plutzky has served on cardiovascular trial steering committees including SELECT (GLP-1RA semaglutide in obesity, established heart disease but not diabetes).  After University of North Carolina medical school and an NIH research fellowship, Dr. Plutzky did residency and fellowship at BWH/HMS and MIT.

Dr. Moses spent much of his distinguished academic career at Harvard Medical School, rising to Professor of Medicine before joining Novo Nordisk, where he became Senior Vice President and Chief Medical Officer, involved in most aspects of diabetes drug development. A member of diaTribe’s Board of Directors since 2018, he brings decades of leadership in clinical research and innovation to diaTribe’s mission.

Dr. Drucker is an Endocrinologist and Professor of Medicine at the University of Toronto. He holds the Banting and Best Diabetes Centre-Novo Nordisk Chair in Incretin Biology. His laboratory is based in the Lunenfeld Tanenbaum Research Institute at Mount Sinai Hospital in Toronto and studies the molecular biology and physiology of the glucagon-like peptides.